Halozyme Therapeutics (HALO) stock drops after J.P. Morgan downgrade, but analyst raises price target on Enhanze drug ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $61.67, a high ...

On Thursday, JPMorgan adjusted its stance on Halozyme (NASDAQ:HALO) Therapeutics (NASDAQ:HALO), downgrading the stock from Overweight to Neutral, despite increasing the price target from $52.00 to ...

SAN DIEGO, CA – In a recent transaction, Michael J. LaBarre, the Senior Vice President and Chief Technical Officer of Halozyme (NASDAQ:HALO) Therapeutics, Inc. (NASDAQ:HALO), sold shares of the ...

Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $61.93 which represents a decrease of $-0.98 or -1.56% from the prior close of $62.91. The stock opened at $62.91 and touched ...

SAN DIEGO, CA – In a recent transaction, Michael J. LaBarre, the Senior Vice President and Chief Technical Officer of Halozyme (NASDAQ:HALO) Therapeutics, Inc. (NASDAQ:HALO), sold shares of the ...